GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GLP-1 medication

Company
The Cleveland Clinic
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for GLP-1 medication and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06668935

    Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

    Abbott Diabetes Care 800 participants Est. completion 2027-01 2 sites
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Recruiting NCT NCT06843512

    Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

    Penn State University 25 participants Est. completion 2026-12 1 site
    Other conditions: Weight Loss, Food Selection
    View official trial listing →
  • Recruiting NCT NCT07480109

    Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)

    Not yet reported University of Texas at Austin 75 participants Est. completion 2027-09-30 2 sites Stand-alone
    Other conditions: Obesity, Women (Between 30 to 60 Years Old)
    View official trial listing →
  • Recruiting NCT NCT07806838

    Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication

    Not yet reported University of California, Los Angeles 75 participants Est. completion 2028-09-01 1 site
    Other conditions: Obesity & Overweight, Muscle Mass and Strength, Muscle Function
    View official trial listing →
  • Completed NCT NCT06533527

    Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

    Not yet reported The Cleveland Clinic 69 participants Est. completion 2025-05-20 2 sites
    Type 2 diabetes Other conditions: Obesity, Gastroparesis
    View official trial listing →
  • Not yet recruiting NCT NCT06927401

    Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users

    Not yet reported Asian Institute of Gastroenterology, India 36 participants Est. completion 2025-08-30 1 site Stand-alone
    Other conditions: Endoscopy, Digestive System, GLP1-R-related Disease
    View official trial listing →
  • Active, not recruiting NCT NCT06939517

    Acupressure Wristbands for GLP-1RA Related Nausea

    Not yet reported Florencia Ziemke 35 participants Est. completion 2025-04-13 1 site
    Other conditions: Nausea
    View official trial listing →
  • Not yet recruiting NCT NCT07032311

    Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk

    Not yet reported SIPPA Solutions INC 200 participants Est. completion 2027-06-30 1 site Stand-alone
    Type 2 diabetesPrediabetes Other conditions: Liver Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07130396

    Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication

    Not yet reported Metagenics, Inc. 100 participants Est. completion 2026-04-30
    Other conditions: GLP-1, Adults
    View official trial listing →
  • Terminated NCT NCT07190794

    RESCUE: Discontinuation of GLP-1

    Boston Scientific Corporation 18 participants Est. completion 2026-05-26 1 site
    Other conditions: Obesity
    View official trial listing →
  • Enrolling by invitation NCT NCT07404150

    Lifestyle Program Focused on Nourishment, Well-Being, and Health Behaviors in Women With Obesity

    Heather Conradson 60 participants Est. completion 2027-09-15 1 site
    Other conditions: Obesity and Cardiovascular Risk
    View official trial listing →
  • Not yet recruiting NCT NCT07588984

    GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

    Noom Inc. 2310 participants Est. completion 2029-05 1 site
    Cardiovascular disease Other conditions: Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.